Journals / Retina-Vitreus / 2010 / Cilt: 18 - Sayı: 4

Photodynamic therapy results in age-related macular degeneration

Yaşa bağlı maküla dejenerasyonu hastalarında fotodinamik tedavi sonuçları

Pages
289–296
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no significant difference in visual loss between the two groups but the loss in the successful group was 1.5 LogMAR standard lines less than that in the unsuccessful group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy of photodynamic therapy in patients who had choroidal neovascularization due to agerelated macular degeneration (AMD).
📊
Key Findings & Data:Materials and Methods: Data on 30 eyes of 30 patients were evaluated.
💡
Conclusion & Impact:There was no significant difference in visual loss between the two groups but the loss in the successful group was 1.5 LogMAR standard lines less than that in the unsuccessful group.
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficacy of photodynamic therapy in patients who had choroidal neovascularization due to agerelated macular degeneration (AMD). Materials and Methods: Data on 30 eyes of 30 patients were evaluated. Sixteen patients were men and 14 were women. Mean age was 68.4±8.74 (47 to 81 years) years. Mean follow-up time was 15.7±3.28 months (10-22 months). The patients’ best corrected visual acuities were measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) chart number 2 and lesion types and the GLD of the lesions were measured by Topcon Image Net Fundus Camera. The indication for photodynamic therapy was based on the European Ophthalmology Society’s criteria published in 2001. The patients were invited to undergo control examinations 1 week and 3 months after the therapy and thereafter every 3 months. In each control examination the best corrected visual acuity was checked by ETDRS chart, fundus examinations were performed and fundus photographs were recorded by fundus camera, and FFA examinations was performed, especially in the first and second controls. Results: After 2±1.44 therapies (ranging from 1 to 5) 22 patients (73.3%) could have been treated, but 8 patients (27.7%) had persistent CNVs. There was no significant difference in visual loss between the two groups but the loss in the successful group was 1.5 LogMAR standard lines less than that in the unsuccessful group.

Özet

Amaç: Bu çalışmada fotodinamik tedavinin yaşa bağlı maküla dejenerasyonda gelişen koroidal neovaskülarizasyonların tedavisindeki etkinliği değerlendirildi. Gereç ve Yöntem: Çalışmaya 30 hastanın 30 gözü alındı. Hastaların 16’sı (%53.3) erkek, 14’ü (%47.7) kadındı. Hastaların yaş ortalaması 68.4±8.74 (47-81 yaş), ortalama takip süresi 15.7±3.28 ay (10-22 ay) idi. Tedavi öncesi hastaların en iyi düzeltilmiş görme keskinlikleri Early Treatment of Diabetic Retinopathy Study 2 numaralı eşeli ve lezyon tipleri ve lezyon büyüklükleri fundus kamera ile ölçüldü. Hastalara fotodinamik tedavi endikasyonu Avrupa Oftalmoloji Cemiyeti’nin 2001 yılında yayınladığı rehbere göre kondu. Hastalar FDT sonrası 1. hafta, 3. ay ve sonrasında her üç ayda bir kontrol edildi. Kontrollerde ETDRS eşeli ile en iyi düzeltilmiş görme keskinlikleri, fundus muayeneleri ve fundus kamera ile renkli fundus görüntüleri alındı ve özellikle ilk ve ikinci kontrollerde FFA’ları çekildi. Hastalar kontrollerinde FFA’daki florosein sızdırma özelliklerine göre dört gruba ayrıldılar ve sızıntının olmadığı durumlar ile sızıntının %50’den daha az hale geldiği durumlarda tedavi başarılı, sızıntının %50’den fazla olduğu durumlarda ise başarısız kabul edildi. Bulgular: Ortalama 2±1.44 (1-5) seanslık tedavi sonucunda 22 (%73.3) olguda KNV’nin gerilediği, 8 (%27.7) olguda ise KNV’nin devam ettiği tespit edildi. Başarılı grupla başarısız grup görme kaybı açısından değerlendirildiğinde başarılı grupta ortalama 1.5 LogMAR standart sırası daha az görme kaybı gelişti fakat aradaki fark istatistiksel olarak anlamlı değildi. (p=0.101). Tartışma: Sonuç olarak Verteporfin ile FDT ile Eksudatif tip YBMD tedavisinde etkili ve güvenli bir yöntemdir.

🔖

Cite This Article

ÖZKAYA, A., GÜRCAN, Z., YİĞİT, U., GÜLTEKİN, Ö. E., ÖZKAYA, H. M. (2010). Photodynamic therapy results in age-related macular degeneration. Retina-Vitreus, Cilt: 18 - Sayı: 4, 289–296. https://ajindex.com/articles/307930

References (15)

  1. Cruischshanks KJ, Hamman RF, Klein R, et al.: The prevalence of age-related maculopathy by geographic region and ethnicity: The Colorado-Wisconsin study of age related maculopathy. Arch Ophtalmol. 1997;115:242-250
  2. Hirvela H, Luukinen H, Lic EL, et al.: Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology. 1996;103: 871-877
  3. Van Leeuwen R, Klaver CCW, Vingerling JR, et al.: Epidemiology of age-related maculopathy: a review. European Journal of Epidemiology. 2003;18:845-854
  4. Vingerling JR, Dielemans I, Hofmann A ve ark.: The prevalence of age-related maculopathy in Rotterdam eye study. Ophthalmology. 1995;102:205-210
  5. Mitchell P, Smith W, Attebo K, Wang JJ.: Prevalence of age-related maculopathy in Australia: the Bluemountains eye study. Ophthalmology. 1995:102;1450-1460
  6. Klein R, Klein BEK, Linton KLP.: Prevalence or agrelated maculopathy: The Beaver Dam Eye Sudy. Ophthalmology. 1992;99:993-943
  7. Klein R, Peto T, Bird A, et al.: The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486-495
  8. Flynn HW, Bressler SB, Brown GC, et al.: Age-related macular degeneration in Retina-Vitreus. Liesegang TJ, Gregory LS, Cantor LB. San Francisco. American Academy of Ophthalmology. 2003;49-76
  9. Algvere PV, Seregard S.: Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand. 2002;80:136-143
  10. Ciulla TA, Danis RP, Haris A.: Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol. 1998;43: 134-146
  11. Hart PM, Chakravarthy U, MacKenzie G, et al.: Teletherapy for subfoveal choroidal neovascularisation of age-related macular degeneration: results of follow up in a non-randomised study. Br J Ophthalmol. 1996;80:1046-1050
  12. Soubrane G, Souied E, Haddad W, et al.: Alternative therapies for choroidal neovessels resulting from age-related macular degeneration. J Fr Ophtalmol. 2003;26: 876-878
  13. Hooper CY, Guymer RH.: New treatments in age-related macular degeneration. Clin Experiment Ophthalmol. 2003;31:376-391
  14. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231
  15. Gillies MC, Sarks JP, Beaumont PE, et al.: Treatment of choroidal neovascularisation in age-related macular degeneration with interferon α 2a and α 2b. Br J Ophthalmol. 1993;77:759-765